Barchart Demo Center

Overview

Stocks

Stock Screeners

ETFs

Futures

Funds

Fund Screeners

Foreign Exchange

Sectors

News

Financial Calculators

Embedded Widgets

Portfolio

Screener

JSON Feeds

Symbol Overview

United States|Canada
English|French

Kempharm Inc

(NASDAQ: KMPH)
Add to Portfolio
-0.05 (-7.81%)
as of Oct 18, 2019

Profile
Ticker Symbol KMPH
Exchange NASDAQ
Contact Information
1180 Celebration Boulevard Suite 103
Celebration, FL USA
P: 321-939-3416
CEO/President Travis C. Mickle
Earnings at a Glance
Earnings 06/30/19
-0.33
03/31/19
-0.46
12/31/18
0.21
09/30/18
-0.94
Price Earnings Ratio N/A
EPS Growth 53.82
Most Recent Earnings ($) -0.33
Annual EPS ($) -1.93
Business Summary
KemPharm Inc. is a specialty pharmaceutical company which is engaged in the discovery and development of new molecular entity prodrugs. Its product candidates include KP201/APAP KP511/ER and KP606/ER for the treatment of pain; KP415 for the treatment of attention deficit hyperactivity disorder and KP303 for the treatment of central nervous system disorders which are in preclinical trail stage. The Company through its LAT platform technology generate prodrug. KemPharm Inc. is based in CORALVILLE United States.
Industry/Sector Information not available.